Valuation: Theraclion

Market Cap 47.81M 54.72M 43.91M 40.94M 77.62M 5.21B 78.93M 529M 205M 2.56B 205M 201M 8.8B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 55.66M 63.7M 51.12M 47.67M 90.37M 6.06B 91.89M 615M 239M 2.97B 239M 234M 10.25B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
1 day-2.14%
1 week-3.18%
Current month+1.91%
1 month-12.33%
3 months+28.00%
6 months+1.59%
Current year+6.31%
1 week 0.6
Extreme 0.605
0.69
1 month 0.6
Extreme 0.605
0.88
Current year 0.4
Extreme 0.402
0.93
1 year 0.32
Extreme 0.325
1.25
3 years 0.14
Extreme 0.1416
1.25
5 years 0.14
Extreme 0.1416
2.22
10 years 0.14
Extreme 0.1416
7.83
Manager TitleAgeSince
Chief Executive Officer - 2023-05-23
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 2018-01-31
Director/Board Member - 2019-02-12
Director/Board Member - 2019-02-12
Date Insider Type Main position Quantity % Market Cap.
06-07Sell

Director

-25,000 0.0342%
Change 5-day change 1-year change 3-year change Capi.($)
-2.14%-3.18%+96.32%+6.67% 54.72M
+1.97%+3.50%+22.37%+0.32% 195B
+5.87%+6.59%-21.20%+24.59% 151B
+2.17%+2.44%-2.26%-17.53% 140B
+4.83%+2.13%-56.44%-16.55% 67.09B
+2.59%+5.18%+22.53%+0.04% 54.34B
-0.39%+1.61%-25.91%-31.39% 44.64B
-2.02%-3.56%+8.31%+8.68% 36.91B
+0.31%+0.64%+7.78%+42.30% 37.24B
+1.09%+0.96%-13.87%-19.29% 29.82B
Average +0.87%+1.89%+3.76%-0.22% 75.56B
Weighted average by Cap. +1.51%+3.35%-3.57%+0.17%

Financials

2024 2025
Net sales 830K 950K 762K 711K 1.35M 90.45M 1.37M 9.18M 3.56M 44.37M 3.57M 3.49M 153M 652K 746K 599K 558K 1.06M 71.04M 1.08M 7.21M 2.79M 34.84M 2.8M 2.74M 120M
Net income -5.76M -6.59M -5.29M -4.93M -9.35M -627M -9.5M -63.65M -24.67M -308M -24.74M -24.2M -1.06B -5.69M -6.51M -5.22M -4.87M -9.24M -620M -9.39M -62.91M -24.38M -304M -24.45M -23.92M -1.05B
Net Debt 3.41M 3.9M 3.13M 2.92M 5.54M 372M 5.63M 37.71M 14.61M 182M 14.66M 14.34M 628M 7.85M 8.99M 7.21M 6.72M 12.75M 855M 12.96M 86.81M 33.64M 420M 33.74M 33.01M 1.45B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change Volume
26-07-03 0.6400 -2.14% 21,119
26-07-02 €0.6540 -2.82% 26,019
26-07-01 €0.6730 +7.17% 107,254
26-06-30 €0.6280 -1.10% 118,068
26-06-29 €0.6350 -3.93% 47,144

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALTHE Stock